[DOI] [PubMed] [Google Scholar] 123.Cardoso B.R., Cominetti C., Seale L.A
GLP-1 receptor agonists are recommended by NICE when BMI is 35 kg/m (or lower in people of Black African, African-Caribbean, or South Asian family origin) or for whom weight loss would benefit obesity-related comorbidities
Read more Discover how a comprehensive tracking app can transform your GLP-1 medication journey and improve health outcomes
a 2021 peer-reviewed review states plainly that no NNMT-targeted clinical trials have been reported
Monzani E, Nicolis S, DellAcqua S, Capucciati A, Bacchella C, Zucca FA, Mosharov EV, Sulzer D, Zecca L, Casella L (2019) Dopamine, oxidative stress and protein-quinone modifications in Parkinsons and other neurodegenerative diseases